[{"id":"360b90be-2213-4d23-b6e5-cc0f96b7a6e3","acronym":"","url":"https://clinicaltrials.gov/study/NCT04238715","created_at":"2021-01-19T19:12:02.961Z","updated_at":"2025-02-25T14:40:28.907Z","phase":"Phase 2","brief_title":"A Study of E7090 in Participants With Unresectable Advanced or Metastatic Cholangiocarcinoma With Fibroblast Growth Factor Receptor (FGFR) 2 Gene Fusion","source_id_and_acronym":"NCT04238715","lead_sponsor":"Eisai Co., Ltd.","biomarkers":" FGFR2","pipe":" | ","alterations":" FGFR2 fusion","tags":["FGFR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR2 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Tasfygo (tasurgratinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 63","initiation":"Initiation: 01/22/2020","start_date":" 01/22/2020","primary_txt":" Primary completion: 03/31/2026","primary_completion_date":" 03/31/2026","study_txt":" Completion: 03/31/2026","study_completion_date":" 03/31/2026","last_update_posted":"2025-02-14"},{"id":"2354d741-07d7-4fa3-9724-54f92f01122f","acronym":"FORTUNE","url":"https://clinicaltrials.gov/study/NCT04962867","created_at":"2021-07-15T13:06:08.522Z","updated_at":"2025-02-25T13:35:52.987Z","phase":"Phase 2","brief_title":"NCCH2006/MK010 Trial (FORTUNE Trial)","source_id_and_acronym":"NCT04962867 - FORTUNE","lead_sponsor":"National Cancer Center, Japan","biomarkers":" EGFR • KRAS • BRAF • ALK • NRAS • FGFR2 • ROS1 • FGFR4 • NTRK","pipe":" | ","alterations":" EGFR mutation • BRAF mutation • NRAS mutation • BRAF V600 • FGFR2 mutation • FGFR2 fusion • FGFR mutation","tags":["EGFR • KRAS • BRAF • ALK • NRAS • FGFR2 • ROS1 • FGFR4 • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • BRAF mutation • NRAS mutation • BRAF V600 • FGFR2 mutation • FGFR2 fusion • FGFR mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tasfygo (tasurgratinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 46","initiation":"Initiation: 06/15/2021","start_date":" 06/15/2021","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-01-08"},{"id":"f6882690-81b0-4166-858f-3df0edb58d54","acronym":"","url":"https://clinicaltrials.gov/study/NCT04572295","created_at":"2021-01-18T21:49:54.892Z","updated_at":"2024-07-02T16:35:28.616Z","phase":"Phase 1","brief_title":"A Study of E7090 as Monotherapy and in Combination With Other Anticancer Agents in Participants With Estrogen Receptor Positive (ER+) and Human Epidermal Growth Receptor 2 Negative (HER2-) Recurrent/Metastatic Breast Cancer","source_id_and_acronym":"NCT04572295","lead_sponsor":"Eisai Co., Ltd.","biomarkers":" HER-2 • ER • FGFR","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • ER • FGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fulvestrant • exemestane • Tasfygo (tasurgratinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 72","initiation":"Initiation: 10/09/2020","start_date":" 10/09/2020","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2023-11-20"}]